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Clycopeptide-resistant Eti terocorcusfaecitim (GREF) and 
Eiitcrococcris faesalis have been called the nosocomial 
pathogens of the 1990s [ I ] .  GREF can be resistant not 
only to glycopeptides but often also to several other 
antibiotics 121. This severely limits the available 
therapeutic options for treatment of infections with 
these organisms. This is likely to be particularly true in 
neonatal units, where there are even fewer options for 
antibiotic therapy. We describe the investigation and 
management of an outbreak of GREF in a neonatal 
unit; few, if any, reports of this have been previously 
published. 
The neonatal unit at Lewisham Hospital is designed 
to admit up to 16 patients. O n  27 March 1996 a strain 
of GKEF was isolated from blood cultures taken from 
a baby on the unit. O n  10 April blood cultures taken 
from two other babies on the unit also yielded GREF 
strains with identical susceptibility profiles. It was 
decided that these strains constituted a possible out- 
break, and appropriate investigative and control measures 
were inipleinented. The outbreak was contained by 
1 May 1996. 
Microbiological investigations showed 12 of the 43 
babies of both sexes admitted to the unit during the 
outbreak to be colonized with GKEF. All affected 
babies were admitted between 25 January 1996 and 22 
April 1996. The age of the babies ranged from 24 to 
40 weeks, and they were admitted to the unit for a 
variety of reasons, including prematurity, surgery and 
neonatal coniplications. Many of the babies had been 
treated with teicoplanin for possible sepsis caused by 
Stuplzyloraccr~s cpidcvrnidis isolated froin blood cultures 
taken during episodes of clinical deterioration. Although 
three of the babies had blood cultures positive for 
GKEF, these were not considered to be clinically 
significant by the pediatricians, and the babies were not 
given any specific treatment. Kepeat blood cultures 
were negative. All 12 affected babies had gastrointestinal 
colonization with GREE 
The neonatal unit has three rooms where the 
patients were treated. Babies in rooni 1 required the 
most intensive nursing care, and those in room 3 the 
least. The first carrier was detected in room 2. 
Subsequent carriers were distributed between all three 
rooms in the unit. Perusal of the medical and nursing 
records established that many of the carriers had been 
transferred from one room to another prior to the 
detection of the outbreak. These transfers mainly 
reflected particular nursing requirements. We also 
observed that each transfer of a carrier to a new 
location was associated with developnient of secondary 
carriers. 
Rectal swabs and other clinical specimens were 
screened using a selective medium containing vanco- 
niycin [3]. Presumptive glycopeptide-resistant entero- 
coccal strains (1 1 GREF and one E. gallirzunim) were 
confirmed by referral to the Antibiotic Keference 
Unit, Colindale, London. All the GKEF isolates 
were resistant to penicillin, ampicillin, erythromycin, 
vancomycin (MIC >32 mg/L), teicoplanin (MIC 
>128 nig/L), gentainicin and ciprofloxacin, according 
to breakpoint sensitivity testing based on the recom- 
mendations of a working party of the British Society 
for Antimicrobial Chemotherapy [4]. These isolates 
were sensitive to tetracycline, chloramphenicol and 
yuinupristin/dalfopristin (an unlicensed drug belonging 
to the streptogramin class of antibiotics). The in vitro 
antibiotic susceptibility tests were initially done by the 
comparative disk diffusion method (Stoke's method) at 
the Lewishani Hospital and later confirmed at the 
Antibiotic Keference Unit by the agar dilution method. 
All GREF isolates carried tauzA4 genes and were 
also indistinguishable by pulsed-field gel electrophoresis 
(PFGE) using methods described previously 151. 
Environinental screening, which included surfaces, 
sinks, incubators and other equipment, did not detect 
any GREF isolates. Parents and staff were not screened 
because the published literature did not suggest that 
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exclusion of carriers or measures to eliminate carriage 
contribute to the management of GREF outbreaks [6]. 
The outbreak was managed through cohort nursing 
and stringent hand hygiene. In addition, guidelines to 
restrict the use of cephalosporins and glycopeptides 
to unequivocal cases of sepsis and central venous 
catheter (CVC)-associated infection, respectively, were 
instituted. No specific antibiotic therapy was given for 
the eradication of GRXF. Although the outbreak was 
deemed to have ended by 1 May 1996, surveillance for 
GREF continued until either the affected babies were 
discharged to their homes or there was clearance of 
fecal carriage. A majority of the affected babies had 
spontaneous clearance of GFLEF within 6-8 weeks. 
This outbreak of GREF highlights several aspects 
of the epidemiology and measures for control of GREF 
in a neonatal unit. We have demonstrated the spread of 
GREF in a neonatal unit using traditional epidemio- 
logic methods in conjunction with molecular methods. 
The traditional approach has merit in that it demon- 
strated clearly how the infection was spread in the unit, 
and is particularly relevant in that in neonatal units it is 
conventional to transfer babies from one area to another 
according to the level of care required. Identified risk 
factors for the acquisition of GREF are most often 
prior consumption of glycopeptides and cephalo- 
sporins [2,5-71. Excessive use of teicoplanin to treat 
suspected S. epidermidis infections on the unit is likely 
to have played an important role in the selection of 
GREF in the gastrointestinal tract [6,7]. 
As it is difficult to obtain blood cultures aseptically 
in neonates, contamination with S. epidevmidis is 
extremely common and can be misleading [8]. Pedia- 
tricians should resist the temptation to treat these 
isolates unless there is unequivocal evidence of sepsis, 
usually associated with the presence of CVCs. 
Removal/replacement of long lines should be an 
integral part of the management of CVC-associated 
sepsis. 
Fortunately, in this situation none of the affected 
babies required treatment. This, however, should not 
detract from the fact that the few antibiotics available 
for treatment were either contraindicated in children 
(tetracycline) or unlicensed (quinupristin/dalfopristin) . 
It is likely that the spread of GREF in the unit was 
controlled by emphasizing the importance of hand 
hygiene and rationalizing the use of cephalosporins and 
teicoplanin. 
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